潘托普拉用于预防机械通风患者上部胃肠道出血的成本效益
Feng Xie1,2, Yifan Yao1, Yue Ma1
1Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.
JAMA network open
|December 1, 2025
概括
每日服用潘托普拉可显著降低危急病症,机械通风患者的上部胃肠道出血. 这种策略既更有效,又比不使用潘托普拉更便宜,提供了经济价值.
科学领域:
- 关键护理医学 关键护理医学
- 卫生经济学 卫生经济学
- 胃肠病学 胃肠病学
背景情况:
- 上部胃肠道出血 (UGIB) 是需要机械通风的重症患者的一个重大问题.
- 潘托普拉用于预防UGIB,但其在这个人群中的成本效益尚不清楚.
研究的目的:
- 评估每日静脉注射潘托普拉的成本效益与没有潘托普拉相比,用于预防机械通风患者的UGIB.
主要方法:
- 在REVISE试验的同时,还进行了前性健康经济评估.
- 这项研究涉及多个国际地点的4821名入侵通风的重病成年人.
- 从公共卫生保健支付者的角度评估了成本效益,使用加拿大和美国的成本数据.
主要成果:
- 潘托普拉策略与较低的平均每患者总成本 (加拿大美元60,466美元与65,423美元) 相关.
- 潘托普拉更有效,预防临床上重要的上部胃肠道出血.
- 灵敏度分析和模拟始终显示,潘托普拉的成本更低,效率更高 (99%的模拟).
结论:
- 每日静脉注射潘托普拉是一种成本效益的策略,用于预防侵袭性机械通风患者的上部胃肠道出血.
- 这些发现表明,医疗保健系统的临床益处和经济价值.
相关概念视频
Peptic Ulcer Disease IV: Management
394
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
394
Peptic Ulcer Disease V: Surgical Management and Nursing Care
782
Surgical management and nursing care are crucial in treating Peptic Ulcer Disease (PUD). Here is an organized and enhanced overview of the surgical interventions and the associated nursing care for PUD:
Surgical Interventions for Peptic Ulcer Disease
Surgical Interventions for Peptic Ulcer Disease
782
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
812
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
812
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
1.0K
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
1.0K
Gastroesophageal Reflux Disease II: Clinical Features and Management
647
Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
647
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
1.3K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
1.3K


